Study of a new treatment for certain childhood cancers
Part of Brain & nervous system, Cancer clinical trials.
This Phase 1/2 study tests a new therapy for children and young adults with specific types of cancer that have been treated with chemotherapy before. It may help by targeting cancer features in the tumor and using your immune system in a controlled way.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child/you has one of these cancer types: synovial sarcoma, MPNST, neuroblastoma, or osteosarcoma
- Age is 2–17 for synovial sarcoma, or 2–21 for MPNST, neuroblastoma, or osteosarcoma
- You have received systemic chemotherapy before, and you have measurable cancer that can be tracked on scans
- You are HLA-A*02 positive, and the tumor test shows MAGE-A4
- Your overall ability to do daily activities is high enough (ECOG 0–1 if age 16+, or Lansky 80+ if age 2–16)
- No major exclusions such as CNS (brain/spinal) metastases, pregnancy/breastfeeding, active serious infections, or certain immune/autoimmune conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called N-803 for people with synovial sarcoma or myxoid/round cell liposarcoma that has gotten worse after T-cell therapy. N-803 may help the immune system fight the cancer, and the study will see if it can slow or stop the cancer from growing.
This trial tests a combination of two drugs (eflornithine and AMXT 1501) for children and young adults with certain types of cancer that have relapsed or not responded to standard treatment, or for a specific brain tumor (DIPG) at diagnosis. The goal is to see if this drug pair is safe and effective.
This trial tests a new kind of immune therapy using your own natural killer (NK) cells that are specially trained to find and attack cancer cells that have the NY-ESO-1 target. It is for people with certain sarcomas or other advanced solid tumors that have not responded to prior treatments.
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
This Phase 1 study tests an experimental CAR T-cell treatment that targets GD2, with added immune-boosting and safety features, for children with relapsed or refractory neuroblastoma or osteosarcoma. It’s designed to see if the treatment is safe and can shrink these cancers when standard therapy hasn’t worked.
This trial tests a new cell therapy called TBI-1301 (Mip-cel) for people with synovial sarcoma that has spread or come back after chemotherapy. It is designed to help your immune system attack the cancer cells that have a specific marker (NY-ESO-1).
Hear when a new Synovial Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.